Opher Gileadi

Opher Gileadi

SGC Karolinska

Gileadi

Opher Gileadi

Affiliations

Biography

Opher Gileadi obtained his PhD in Biochemistry at the Hebrew University and was then a postdoctoral fellow at Stanford University Medical School. Subsequently he led a research group at the Weizmann Institute of Science. From 2004-2021 he was both at SGC University of Oxford, first as head of the Biotechnology group, then as Principal Investigator of the Genome Integrity & Repair Group as well as Head of the SGC Kinase Chemical Biology Center at the State University of Campinas (UNICAMP). In 2021 Opher took at position as Executive Director, Protein Science and Structure at Exscientia, but re-join the SGC at Karolinska in 2023.

Opher leads the Protein Science team at SGC Karolinska, focussing on developing antibodies and target-enabling packages (TEPs) for under-investigated proteins of humans and pathogens.

2016

Structures of Two Melanoma-Associated Antigens Suggest Allosteric Regulation of Effector Binding.

Newman JA, Cooper CD, Roos AK, Aitkenhead H, Oppermann UC, Cho HJ, Osman R, Gileadi O

PLoS ONE. 2016-2-24 . 11(2):e0148762 .doi: 10.1371/journal.pone.0148762

PMID: 26910052

Identification of LACTB2, a metallo-β-lactamase protein, as a human mitochondrial endoribonuclease.

Levy S, Allerston CK, Liveanu V, Habib MR, Gileadi O, Schuster G

Nucleic Acids Res.. 2016-1-29 . .doi: 10.1093/nar/gkw050

PMID: 26826708

EXD2 promotes homologous recombination by facilitating DNA end resection.

Broderick R, Nieminuszczy J, Baddock HT, Deshpande RA, Gileadi O, Paull TT, McHugh PJ, Niedzwiedz W

Nat. Cell Biol.. 2016-1-25 . .doi: 10.1038/ncb3303

PMID: 26807646

8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.

Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J

J. Med. Chem.. 2016-1-7 . .doi: 10.1021/acs.jmedchem.5b01635

PMID: 26741168

2015

Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.

Korczynska M, Le DD, Younger N, Gregori-Puigjané E, Tumber A, Krojer T, Velupillai S, Gileadi C, Nowak RP, Iwasa E, Pollock SB, Ortiz Torres I, Oppermann U, Shoichet BK, Fujimori DG

J. Med. Chem.. 2015-12-23 . .doi: 10.1021/acs.jmedchem.5b01527

PMID: 26699912

The structures of the SNM1A and SNM1B/Apollo nuclease domains reveal a potential basis for their distinct DNA processing activities.

Allerston CK, Lee SY, Newman JA, Schofield CJ, McHugh PJ, Gileadi O

Nucleic Acids Res.. 2015-11-17 . .doi: 10.1093/nar/gkv1256

PMID: 26582912

Structural basis of metallo-β-lactamase inhibition by captopril stereoisomers.

Brem J, van Berkel SS, Zollman D, Lee SY, Gileadi O, McHugh PJ, Walsh TR, McDonough MA, Schofield CJ

Antimicrob. Agents Chemother.. 2015-10-19 . .doi: 10.1128/AAC.01335-15

PMID: 26482303

Crystal structure of the Bloom's syndrome helicase indicates a role for the HRDC domain in conformational changes.

Newman JA, Savitsky P, Allerston CK, Bizard AH, Özer Ö, Sarlós K, Liu Y, Pardon E, Steyaert J, Hickson ID, Gileadi O

Nucleic Acids Res.. 2015-4-21 . .doi: 10.1093/nar/gkv373

PMID: 25901030